Immunomodulatory potential of mesenchymal stromal cell-derived extracellular vesicles in chondrocyte inflammation.
Animals
Cattle
Humans
Chondrocytes
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Interleukin-6
/ metabolism
Interleukin-8
/ metabolism
Pilot Projects
Cells, Cultured
Inflammation
/ metabolism
Osteoarthritis
/ metabolism
Glycosaminoglycans
/ metabolism
Mesenchymal Stem Cells
/ metabolism
Extracellular Vesicles
/ metabolism
chondrocytes
extracellular vesicles
mesenchymal stromal cells
musculoskeletal immunology
osteoarthritis
tumor necrosis factor alpha
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
03
2023
accepted:
03
07
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Osteoarthritis (OA) affects a large percentage of the population worldwide. Current surgical and nonsurgical concepts for treating OA only result in symptom-modifying effects. However, there is no disease-modifying therapy available. Extracellular vesicles released by mesenchymal stem/stromal cells (MSC-EV) are promising agents to positively influence joint homeostasis in the osteoarthritic surroundings. This pilot study aimed to investigate the effect of characterized MSC-EVs on chondrogenesis in a 3D chondrocyte inflammation model with the pro-inflammatory cytokine TNFα. Bovine articular chondrocytes were expanded and transferred into pellet culture at passage 3. TNFα, human MSC-EV preparations (MSC-EV batches 41.5-EV TNFα supplementation resulted in catabolic stimulation with increased levels of NO and IL-6, upregulation of catabolic gene expression, and downregulation of anabolic markers. These findings were supported by a decrease in matrix differentiation (COL-II). Supplementation of EVs resulted in an upregulation of the chondrogenic marker PRG-4. All MSC-EV preparations significantly increased GAG retention per pellet. In contrast, catabolic markers and IL-8 expression were upregulated by 41.5-EV MSC-EVs can positively influence chondrocyte matrix production in pro-inflammatory surroundings, but can also stimulate inflammation. In this study MSC-EV 41.5-EV
Identifiants
pubmed: 37564645
doi: 10.3389/fimmu.2023.1198198
pmc: PMC10410457
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Interleukin-6
0
Interleukin-8
0
Glycosaminoglycans
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198198Informations de copyright
Copyright © 2023 Ossendorff, Grad, Tertel, Wirtz, Giebel, Börger and Schildberg.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Cell Mater. 2022 Mar 17;43:98-111
pubmed: 35298024
Biochem Soc Trans. 2018 Aug 20;46(4):843-853
pubmed: 29986939
Connect Tissue Res. 1982;9(4):247-8
pubmed: 6215207
Cell Mol Life Sci. 2021 Jan;78(1):79-91
pubmed: 32601714
Int J Mol Sci. 2020 Jun 19;21(12):
pubmed: 32575596
Cell Cycle. 2018 Dec 11;17(24):
pubmed: 30526325
Arch Biochem Biophys. 1961 May;93:440-7
pubmed: 13786180
Tissue Eng Part B Rev. 2021 Feb;27(1):1-13
pubmed: 32159464
Int J Rheum Dis. 2016 Jun;19(6):557-66
pubmed: 25291965
In Vitro Cell Dev Biol Anim. 2019 Mar;55(3):203-210
pubmed: 30783864
Arthritis Res Ther. 2014 Aug 04;16(4):R163
pubmed: 25092378
J Extracell Vesicles. 2021 May;10(7):e12088
pubmed: 34025953
J Inflamm Res. 2022 Apr 21;15:2583-2599
pubmed: 35479833
Tissue Eng. 2006 Nov;12(11):3171-9
pubmed: 17518631
Exp Mol Med. 2019 Oct 4;51(10):1-13
pubmed: 31586040
J Extracell Vesicles. 2018 Oct 17;7(1):1528109
pubmed: 30357008
Front Bioeng Biotechnol. 2020 Dec 14;8:603598
pubmed: 33425869
J Extracell Vesicles. 2020 Mar 09;9(1):1735249
pubmed: 32284824
Curr Stem Cell Res Ther. 2017;12(8):601-610
pubmed: 28595566
Vet Rec Open. 2021 Nov 10;8(1):e22
pubmed: 34795904
Stroke. 2020 Jun;51(6):1825-1834
pubmed: 32312217
Cell Physiol Biochem. 2018;47(1):11-25
pubmed: 29763932
Nat Rev Rheumatol. 2019 Feb;15(2):77-90
pubmed: 30498258
Leukemia. 2014 Apr;28(4):970-3
pubmed: 24445866
Arthritis Care Res (Hoboken). 2013 May;65(5):703-11
pubmed: 23203864
Cytotherapy. 2023 Aug;25(8):821-836
pubmed: 37055321
Stem Cell Rev Rep. 2022 Mar;18(3):933-951
pubmed: 34169411
Cytotherapy. 2023 Feb;25(2):138-147
pubmed: 36244910
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Front Immunol. 2021 Nov 01;12:768771
pubmed: 34790203
JOR Spine. 2020 Jun 19;3(3):e1104
pubmed: 33015577
Am J Sports Med. 2018 Feb;46(2):431-440
pubmed: 29100004
Theranostics. 2018 Jan 1;8(4):906-920
pubmed: 29463990
World J Orthop. 2015 Jan 18;6(1):95-105
pubmed: 25621214
Int J Mol Sci. 2021 Jul 05;22(13):
pubmed: 34281278
Cell Death Dis. 2019 Jul 8;10(7):522
pubmed: 31285423
Cytotherapy. 2023 Aug;25(8):847-857
pubmed: 37097266
Anal Biochem. 1980 Mar 1;102(2):344-52
pubmed: 6158890
Arthritis Rheum. 2003 Dec;48(12):3464-74
pubmed: 14673997
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
World J Stem Cells. 2021 Aug 26;13(8):971-984
pubmed: 34567420
Osteoarthritis Cartilage. 2007 Sep;15(9):1034-41
pubmed: 17442595
Int J Mol Sci. 2021 Aug 03;22(15):
pubmed: 34361116
Front Bioeng Biotechnol. 2019 Jan 29;7:9
pubmed: 30761298
Curr Protoc Stem Cell Biol. 2020 Dec;55(1):e128
pubmed: 32956560
J Orthop Res. 2019 Jun;37(6):1229-1235
pubmed: 31081558
Osteoarthritis Cartilage. 2009 Apr;17(4):464-72
pubmed: 19008124
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
ACS Nano. 2020 Aug 25;14(8):9728-9743
pubmed: 32697573
Cartilage. 2021 Dec;13(2_suppl):204S-212S
pubmed: 32052641
Equine Vet J. 2022 Nov;54(6):1133-1143
pubmed: 34741769
J Orthop Translat. 2021 Sep 20;30:61-69
pubmed: 34611515
Stem Cell Res Ther. 2021 Apr 29;12(1):252
pubmed: 33926561
Biomedicines. 2021 Dec 08;9(12):
pubmed: 34944681
Front Bioeng Biotechnol. 2021 Jan 20;8:624096
pubmed: 33553127
Bioorg Chem. 2021 Aug;113:104978
pubmed: 34052737